{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:34:44Z","timestamp":1773531284335,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67925-7","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T01:01:44Z","timestamp":1721782904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Time to initiate anti-vascular endothelial growth factor therapy and visual outcome in central retinal vein occlusion"],"prefix":"10.1038","volume":"14","author":[{"given":"Chisato","family":"Agata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohdai","family":"Kitamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"67925_CR1","doi-asserted-by":"publisher","first-page":"010427","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song, P., Xu, Y., Zha, M., Zhang, Y. & Rudan, I. Global epidemiology of retinal vein occlusion: A systematic review and meta-analysis of prevalence, incidence, and risk factors. J. Glob. Health 9, 010427 (2019).","journal-title":"J. Glob. Health"},{"key":"67925_CR2","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1167\/iovs.09-4453","volume":"51","author":"M Yasuda","year":"2010","unstructured":"Yasuda, M. et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: The Hisayama study. Investig. Ophthalmol. Vis. Sci. 51, 3205\u20133209 (2010).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"67925_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","volume":"117","author":"PA Campochiaro","year":"2010","unstructured":"Campochiaro, P. A. et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 117, 1102-1112.e1 (2010).","journal-title":"Ophthalmology"},{"key":"67925_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","volume":"117","author":"DM Brown","year":"2010","unstructured":"Brown, D. M. et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 117, 1124-1133.e1 (2010).","journal-title":"Ophthalmology"},{"key":"67925_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown, D. M. et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am. J. Ophthalmol. 155, 429-437.e7 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"67925_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","volume":"97","author":"FG Holz","year":"2013","unstructured":"Holz, F. G. et al. VEGF trap-eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br. J. Ophthalmol. 97, 278\u2013284 (2013).","journal-title":"Br. J. Ophthalmol."},{"key":"67925_CR7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.5301\/ejo.5000162","volume":"22","author":"V Daien","year":"2012","unstructured":"Daien, V. et al. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur. J. Ophthalmol. 22, 1013\u20131018 (2012).","journal-title":"Eur. J. Ophthalmol."},{"key":"67925_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jcjo.2020.09.004","volume":"56","author":"KS Dewan","year":"2021","unstructured":"Dewan, K. S. et al. Age-related differences in presentation and outcomes of anti-VEGF treatment of retinal vein occlusion. Can. J. Ophthalmol. J. Can. Ophtalmol. 56, 96\u2013104 (2021).","journal-title":"Can. J. Ophthalmol. J. Can. Ophtalmol."},{"key":"67925_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10384-014-0305-9","volume":"58","author":"YH Yoon","year":"2014","unstructured":"Yoon, Y. H. et al. Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study. Jpn. J. Ophthalmol. 58, 146\u2013154 (2014).","journal-title":"Jpn. J. Ophthalmol."},{"key":"67925_CR10","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","volume":"123","author":"M Larsen","year":"2016","unstructured":"Larsen, M. et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: Twelve-month results of the CRYSTAL study. Ophthalmology 123, 1101\u20131111 (2016).","journal-title":"Ophthalmology"},{"key":"67925_CR11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","volume":"36","author":"L Nicholson","year":"2022","unstructured":"Nicholson, L., Talks, S. J., Amoaku, W., Talks, K. & Sivaprasad, S. Retinal vein occlusion (RVO) guideline: Executive summary. Eye 36, 909\u2013912 (2022).","journal-title":"Eye"},{"key":"67925_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.oret.2021.02.008","volume":"5","author":"P Sen","year":"2021","unstructured":"Sen, P. et al. Predictors of visual acuity outcomes after anti-vascular endothelial growth factor treatment for macular edema secondary to central retinal vein occlusion. Ophthalmol. Retina 5, 1115\u20131124 (2021).","journal-title":"Ophthalmol. Retina"},{"key":"67925_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.oret.2020.11.010","volume":"5","author":"JG Light","year":"2021","unstructured":"Light, J. G., Tian, J. & Wenick, A. S. Outcomes in retinal vein occlusions presenting with poor visual acuity treated with anti-vascular endothelial growth factor therapy: Prognosis and predictive factors. Ophthalmol. Retina 5, 888\u2013900 (2021).","journal-title":"Ophthalmol. Retina"},{"key":"67925_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3341\/kjo.2010.24.2.83","volume":"24","author":"D-H Lee","year":"2010","unstructured":"Lee, D.-H., Lee, S.-J. & Yoon, I.-N. Clinical progress in impending central retinal vein occlusion. Korean J. Ophthalmol. 24, 83\u201388 (2010).","journal-title":"Korean J. Ophthalmol."},{"key":"67925_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212055","volume":"14","author":"K Azuma","year":"2019","unstructured":"Azuma, K. et al. The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. PLoS One 14, e0212055 (2019).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67925-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67925-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T01:05:13Z","timestamp":1721783113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67925-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67925"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67925-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ryo Obata received honoraria for speaking\/consulting from Santen, Bayer, Novartis, Chugai, Senju and Boehringer Ingelheim. All the other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16974"}}